Notice for mirdametinib (Merck Healthcare Pty Ltd)
Active ingredients
mirdametinib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
dispersible tablets; hard capsules
Indication
Treatment of neurofibromatosis type 1
Therapeutic area
Neurology